Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
THLD
Datos actualizados Fase II SARCOMA
http://www.equities.com/news/headline-story?dt=2012-11-15&val=717465&cat=hcare
a estudiar señores, a estudarlos!
"We are pleased with these results suggesting that TH-302 can be combined with doxorubicin and continued as single agent maintenance treatment for patients with soft tissue sarcoma," said Tillman Pearce, M.D., Chief Medical Officer of Threshold. "These results support our ongoing Phase 3 clinical trial evaluating the potential efficacy and safety of TH-302 plus doxorubicin in extending the lives of patients with soft tissue sarcoma."
TH-302 has been granted Orphan Drug Designation in the U.S. and Europe for the treatment of soft tissue sarcoma.